Special Issue

Biomarkers in Diagnosis and Treatment of Pulmonary Disease

Message from the Guest Editors

The lungs and airways are affected by several pathologies such as inflammation, infection and cancer. The combination of biomarkers yields more information when analyzing the association between systemic inflammation and lung function. Indeed, pulmonary biomarkers may be useful in diagnosis, predicting disease progression, indicating disease instability and predicting response to current therapies and novel therapies, many of which are now in development. Studies have shown that abnormally developed lung structure and function may contribute as susceptibility factors in several adult lung diseases such as COPD, cystic fibrosis and asthma, caused by many etiologies, including genetic–environmental interactions. Thus, lung development and pathogenesis are connected, indicating the need to identify more biomarkers at early stages. □n this Special Issue, we welcome the submission of original research studies (either clinical or basic), meta-analysis and state-of-the-art reviews related to pulmonary diseases. Focus will be placed on the identification of biomarkers in the context of precision medicine for patients with pulmonary diseases.

Guest Editors

Dr. Kelly Domvri
1. Department of Pathology, General Hospital of Thessaloniki 'Georgios Papanikolaou, Thessaloniki, Greece
2. Pulmonary Department, Aristotle University of Thessaloniki, George Papanikolaou Hospital, Thessaloniki, Greece

Dr. Konstantinos Porpodis
Pulmonary Department, General Hospital of Thessaloniki 'Georgios Papanikolaou', Aristotle University of Thessaloniki, Thessaloniki, Greece

Deadline for manuscript submissions

closed (25 April 2025)

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:
indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:
CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).